{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024983","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.112985+00:00","generated_at":"2026-06-21T20:51:48.376528+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Arcellx Q3 net loss $92.9M; initiates pivotal iMMagine-1 study for CART-ddBCMA","bullets":["Net loss of $92.9M vs $17.1M in Q3 2021, driven by $63.1M non-cash Lonza lease expense.","Cash, equivalents, and marketable securities of $280.8M as of Sep 30, 2022; funds operations for at least 12 months.","Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA in relapsed/refractory multiple myeloma.","Longer-term Phase 1 CART-ddBCMA data to be presented at ASH Annual Meeting in December 2022.","Plan to initiate Phase 1 ARC-SparX trial (ACLX-002) in AML/high-risk MDS by year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024983","json":"https://secwatch.observer/filing/0000950170-22-024983.json","markdown":"https://secwatch.observer/filing/0000950170-22-024983.md","text":"https://secwatch.observer/filing/0000950170-22-024983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000095017022024983/0000950170-22-024983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000095017022024983/aclx-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:51:48.376528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d17ffa007aa93bd2eac7d508bdc36069dbcdf9f","claim":"Arcellx, Inc. reported the fiscal quarter ended September 30, 2022 results: net income $92.9 million.","evidence_excerpt":"Net loss was $92.9 million and $17.1 million for the quarters ended September 30, 2022 and 2021, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1786205/000095017022024983/0000950170-22-024983-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2022"},{"label":"Net income","value":"$92.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}